BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Cancer / Immunology

GC Genome Enables Prognosis Prediction and Targeted Treatment in Breast Cancer

''We can gain vital insights into patient prognosis and make informed decisions regarding the most effective treatment strategies through ctDNA CNA...

July 27, 2023 | News

HaemaLogiX, Peter MacCallum Cancer Centre Announce Myeloma CAR-T Trial Agreement

HaemaLogiX and Peter MacCallum Cancer Centre have entered a collaboration agreement to develop and conduct the first Phase I human trial of HaemaLogiX's ...

July 26, 2023 | News

Clarity reaches 50% recruitment milestone for Phase II SABRE prostate cancer trial

SABRE (Copper-64 SAR-Bombesin in Biochemical Recurrence of prostate cancer) is a Phase II Positron Emission Tomography (PET) imaging tr...

July 25, 2023 | News

BGI Genomics Global Cervical Cancer Survey Finds Young Women Have Higher Vaccination Rates but 43.5 percent Put off by Pap Smears

To further inform action to combat cervical cancer, the fourth most common cancer among women globally, BGI Genomics released its State of Cervi...

July 24, 2023 | News

Doer Biologics Announces License Agreement with BioNTech

Under the terms of the agreement, Doer Bio will grant BioNTech a worldwide license to utilize one of Doer Bio's innovative discoveries to research, develop...

July 12, 2023 | News

NK:IO Secures £1.6M Innovate UK Grant for Pioneering Cancer Therapy

Grant award of £1.6M supports program of development work with Cell and Gene Therapy Catapult NK:IO’s platform, based on pionee...

July 11, 2023 | News

3D bioprinting technology to be used for removing cancer cells

□ A three-dimensional (3D) bioprinting technology capable of eliminating cancer cells using the function of immune cells has been developed for t...

July 11, 2023 | News

280 Bio receives IND approval from the FDA for YL-17231

80Bio, Inc. a clinical stage biotechnology company focused on the development of precision oncology medicines, today announced that the U.S. Food and Drug ...

July 10, 2023 | News

Hexvix® Completes Phase III Bridging Trial Enrollment for Bladder Cancer

The study is a prospective, self-controlled, multicenter Phase Ⅲ trial aimed at investigating the additional detection rate and safety of Hexvix®&nbs...

July 10, 2023 | News

GeneQuantum Healthcare and Aimed Bio collaborate to develop 5 innovative ADC drugs

Since April of last year, GeneQuantum and Aimed Bio have been collaborating on the joint development of a FGFR3-targeting ADC named GQ1011/AMB302. The prog...

July 07, 2023 | News

I-Mab Publishes Givastomig, a Claudin18.2 x 4-1BB Bispecific Antibody, in JITC

Givastomig is engineered to bind to CLDN18.2-expressing cancer cells and co-stimulatory receptor 4-1BB on adjacent T cells, with the aim of activating...

July 06, 2023 | News

FDA Approves Cu-64 SAR-bisPSMA Phase III Trial for Prostate Cancer

FDA agreement for a pivotal Phase III trial for 64Cu SAR-bisPSMA diagnostic in prostate cancer Phase III trial design based on&n...

July 05, 2023 | News

Jacobio Receives CDE Approval for Glecirasib's Pancreatic Cancer Pivotal Study in China

The pivotal clinical trial approved in China will evaluate the efficacy and safety of Glecirasib as a single agent for the second line treatment ...

July 05, 2023 | News

Innovent and IASO Bio Receive NMPA Approval for FUCASO®, a Fully-human BCMA CAR-T Therapy for Multiple Myeloma

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality me...

July 03, 2023 | News

Stay Connected